National Institute for Health and Clinical Excellence (NICE)
New NICE quality standard to improve care of people with psychosis and schizophrenia
The National Institute for Health and Care Excellence (NICE) has issued a new quality standard to help adults with psychosis and schizophrenia have a positive experience of mental health services and ensure they receive the support they need .
Psychosis and schizophrenia cover a range of disorders in which a person’s thoughts, mood and behaviour are significantly altered. Each person will have a unique combination of symptoms and experiences. They can include hallucinations, delusions, social withdrawal or self-neglect.
Recent figures showed that up until 2009, there were about 17,000 new cases of psychosis and 8,000 new cases of schizophrenia in England each year2.
People with severe mental illness such as schizophrenia often die 15-20 years earlier than people without a severe mental illness3. There may be several reasons why. For instance, many people with psychosis and schizophrenia will often have other health problems such as heart disease and diabetes, that can be made worse by antipsychotic drugs.
The latest service audit showed an increase in the number of people with schizophrenia receiving physical health checks; however this was still only a third of service users4. The quality standard includes a statement to continue to drive improvements, calling for regular health checks to be prioritised. Healthcare professionals should monitor weight, waist and blood pressure measurements with results to be shared with a person’s GP and mental health team.
In 2014, only 7% of people using mental health services were in paid employment5. The latest audit of schizophrenia services also found that less than half (48%) of those who wanted to find work felt they got any help job hunting4. The quality standard stresses the need for structured employment programmes to be made available to people with psychosis and schizophrenia who would like to find work.
Other priorities in the quality standard cover the treatment of people with psychosis and schizophrenia, as well as support for their family and carers including:
- Ensuring people who have a first episode of psychosis start treatment in an early intervention in psychosis service within 2 weeks of being referred.
- Offering cognitive behavioural therapy for psychosis to help people with psychosis and schizophrenia cope with their symptoms.
- Providing education and support programmes for carers.
Professor Gillian Leng, deputy chief executive and director of health and social care for NICE, said: “Psychosis and the specific diagnosis of schizophrenia are serious mental illnesses that have debilitating symptoms and can affect all aspects of a person’s life. Many people with severe mental illness will also suffer from additional health problems, like heart disease and diabetes, which can significantly affect how long they live. Other symptoms such as a lack of drive or social withdrawal, means they might also struggle to contribute to society.
“We are seeing improvements in mental health services but there is still some way to go before we can be sure that all people with psychosis and schizophrenia are getting high-quality care. There are certain areas such as offering health checks, providing access to psychological therapies and employment support, where we know more still needs to be done to drive improvements in care.
“With this new quality standard we want to highlight what health and social care services need to prioritise to make sure all people with psychosis and schizophrenia are getting the care they need and deserve.”
Mark Winstanley, chief executive officer of Rethink Mental Illness said: “We know from our supporters that thousands of people with psychosis and schizophrenia are still missing out on a range of effective services and support which could transform their lives.
“These quality standards highlight where improvements in care need to be made, including making sure everyone with psychosis gets proper treatment for their physical health, and improving access to early intervention support and talking therapies.
“Now we urge mental health professionals, service providers and local commissioners to act on the quality standards, and ensure that they inform the provision of better quality care for people with psychosis and schizophrenia in their communities.”
The full quality standard which includes 8 statements is available at/guidance/QS80.
For more information call the NICE press office on 0300 323 0142 or out of hours on 07775 583 813.
Notes to Editors
- The quality standard is available at /guidance/QS80.
- A 2012 review of the incidence of schizophrenia and psychosis found a pooled incidence of 31.7 per 100,000 person-years for psychosis and 15 per 100,000 person-years for schizophrenia in England between 1950 and 2009.
Kirkbride JB, et al. Incidence of schizophrenia and other psychoses in England, 1950–2009: a systematic review and meta-analyses. PLoS ONE 7(3): e31660
- Schizophrenia Commission. The Abandoned Illness. 2012.
- Royal College of Psychiatrists. Report of the National Audit of Schizophrenia (NAS) 2014.
- Health and Social Care Information Centre. Measures from the Adult Social Care Outcomes (2013-14). 2014.
About NICE quality standards
NICE quality standards aim to help commissioners, health care professionals, social care and public health practitioners and service providers improve the quality of care that they deliver.
NICE quality standards are prioritised statements designed to drive measurable quality improvements within a particular area of health or care. There is an average of 6-8 statements in each quality standard.
Quality standards are derived from high quality evidence-based guidance, such as NICE guidance or guidance from NICE accredited sources, and are produced collaboratively with health care professionals, social care and public health practitioners, along with their partner organisations, patients, carers and service users.
NICE quality standards are not mandatory but they can be used for a wide range of purposes both locally and nationally. For example, patients and service users can use quality standards to help understand what high-quality care should include. Health care professionals and social care and public health practitioners can use quality standards to help deliver high quality care and treatment.
NICE quality standards are not requirements or targets, but the health and social care system is obliged to have regard to them in planning and delivering services, as part of a general duty to secure continuous improvement in quality.
Quality standard topics are formally referred to NICE by NHS England (an executive non-departmental public body, established in October 2012) for health-related areas, and by the Department of Health and Department for Education for areas such as social care and public health.
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for driving improvement and excellence in the health and social care system. We develop guidance, standards and information on high-quality health and social care. We also advise on ways to promote healthy living and prevent ill health.
Our aim is to help practitioners deliver the best possible care and give people the most effective treatments, which are based on the most up-to-date evidence and provide value for money, in order to reduce inequalities and variation.
Our products and resources are produced for the NHS, local authorities, care providers, charities, and anyone who has a responsibility for commissioning or providing healthcare, public health or social care services.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Thousands of breast cancer patients to have routine access to NICE-approved drug combination01/03/2021 15:28:15
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for routine use after draft guidance from NICE recommended ribociclib (also called Kisqali and made by Novartis) is taken out of the Cancer Drugs Fund (CDF).
Hundreds of people set to benefit as NICE recommends selective internal radiation therapy for treating advanced liver cancer26/02/2021 16:15:00
Hundreds of people with advanced liver cancer (also called hepatocellular carcinoma or HCC) are set to benefit after NICE today (26 February 2021) published final draft guidance recommending a cancer treatment called selective internal radiation therapy (SIRT) as an option for treating the condition.
NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE25/02/2021 15:20:00
NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more data can be collected while patients can access the treatment.
NICE draft guidance recommends sapropterin for children with rare inherited metabolic condition phenylketonuria25/02/2021 14:15:00
NICE has today (25 February 2021) issued draft guidance for public consultation which recommends sapropterin (also called Kuvan and made by BioMarin) for treating phenylketonuria (PKU) in children aged up to 18.
A new instrument for consideration of a broader range of benefits for people, their families and carers18/02/2021 14:15:00
Blog posted by: Bhash Naidoo Senior Technical Adviser – Health Economics at NICE, 17 February 2021.
Skin cancer drug recommended for routine NHS use15/02/2021 09:15:00
An appeal period has now opened until 26 February 2021.
NICE recommends treatment options for severe pregnancy sickness in new draft guidance11/02/2021 15:15:00
Nausea and vomiting, often referred to as morning sickness, is common in pregnancy. Close to 80% of pregnant women experience these symptoms, with most conditions improving or stopping completely by around 16 to 20 weeks
NICE’s processes of technology evaluation - presenting a case for change04/02/2021 15:20:00
NICE has today (4 February 2021) launched a public consultation on proposals for changes to the processes it uses to develop its guidance on medicines, medical devices, diagnostics and digital health technologies